An asset doesn't have a value.
It has a distribution.

The situation

Oncolytic viruses have gone from fringe idea to one of immuno-oncology's most active frontiers. That's the problem. When a field gets hot, everyone crowds into the same handful of indications — melanoma, head and neck, colorectal, lung. A team entering now doesn't just need to know the science works. They need to know where the science works and nobody else is looking.

Our client wanted that second answer. Not a literature review. A decision.

What we did

We started with the biology, because a commercial call built on shaky science ages badly. We worked through the major viral platforms — HSV, adenovirus, vaccinia, reovirus and others — and the mechanisms that actually drive anti-tumor response, including how oncolytic viruses turn immunologically “cold” tumors “hot” and set them up for checkpoint inhibitors. That gave us a real basis for judging which tumors are a good biological fit, rather than guessing.

Then we mapped the competition — every asset we could find, sorted by clinical phase and by target disease. The picture that came back was the kind of thing that stays invisible until you plot it: a dense cluster of programs fighting over a few indications, and a set of high-need cancers with almost nobody in them. We pulled in the money too — recent financings, big-pharma acquisitions and licensing deals, and where investor attention was actually flowing.

Finally we scored it. The prioritization matrix weighed three things a developer has to trade off: unmet medical need, how crowded the research space already is, and how well the tumor's biology suits the modality. Every indication got a score and a rank, so the recommendation wasn't a matter of opinion — it was something the client could interrogate, argue with, and defend to a board.

What we found

Seven indications rose out of the top-15 shortlist as genuine greenfield plays, several with orphan-drug potential. Soft-tissue and bone sarcoma and neuroblastoma came out on top: high unmet need, very little competition, and tumor characteristics that lend themselves to the modality. Esophageal, renal, prostate and glioblastoma filled out the ranked list, each with its own risk-reward profile spelled out.

The headline wasn't “oncolytic viruses are promising.” Everyone knows that. The headline was a specific, ordered list of where to go first — and why.

Why it mattered

A first-in-class position in a well-chosen indication is worth far more than a me-too program in a crowded one. By tying scientific fit to the competitive gap, the client got a defensible starting point for R&D focus, orphan-drug strategy and partnering conversations — the difference between “we could do oncolytic viruses” and “here's the case for starting with sarcoma.”

The situation

Valuing an early-stage drug company is where a lot of analysis quietly falls apart. The asset had cleared Phase 1 — safety, tolerability, oral bioavailability — with an interesting, first-in-concept mechanism and a licensing-based business model. Promising, but promising is not a number. Investors and partners needed to know what the company was worth today, whether the market was as big as the pitch suggested, and whether the proposed milestone-and-royalty scheme was fair to everyone at the table.

Standard discounted cash flow doesn't handle this well. It ignores the thing that defines biotech: at every clinical phase, the program might simply fail. Any honest valuation has to price that in.

What we did

We valued the risk, not around it. We built a real-options valuation model on the company's actual decision tree — the option to abandon after an efficacy failure, the option to switch to a backup molecule after a safety failure. Each path carries its own probability, so the firm's value comes out as a genuinely risk-adjusted expected NPV rather than a hopeful base case with a discount applied on top.

We built the market from the bottom up. Instead of borrowing a top-line market figure, we constructed a demographic-economic model: population projections and incidence rates by age group, the share of patients failing existing treatment, realistic penetration assumptions, and willingness-to-pay anchored to the price of complementary therapies. For the lead oncology indication that produced a current addressable market near $10.3 billion a year; the secondary vaccine indication added its own smaller stream.

We pressure-tested the story. Pricing was sanity-checked against competitor economics and haircut for a competitor the company's own reports had left out. We mapped the competitive landscape, including a near-identical program that had already failed in the clinic — a detail that matters a great deal when underwriting a first-in-concept bet. Commercial strategy, supply chain and IP position were all modelled, with a SWOT to keep the assumptions honest.

We checked both sides of the deal. We didn't just value the company; we modelled the licensing payment scheme and confirmed it was viable and attractive from the partner's perspective too. A deal only closes when the math works for everyone.

What we found

The model returned a business value of roughly $505M for a fully integrated version of the project, and a company value of about $62M under the actual licensing structure. The gap told a clear story: an early investor stepping in at that point could see invested value multiply substantially as clinical risk was retired. We also showed how value climbs as each milestone clears, so the client could see exactly which de-risking events move the needle.

Just as useful were the negatives. Two of the indications the company was excited about destroyed value in our model — one for a thin, low-margin market, the other because the runway to patent expiry was too short to earn back the R&D. Knowing what not to fund is part of the job.

Why it mattered

The client walked away with a number they could defend, a market estimate built from the ground up rather than borrowed, and a deal structure checked from both sides of the table. That's what turns “this looks interesting” into a decision an investment committee can sign off on.